Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
112 hedge funds and large institutions have $793M invested in Genomic Health, Inc. in 2014 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 38 reducing their positions, and 8 closing their positions.
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
11% more funds holding
Funds holding: 101 → 112 (+11)
5% more capital invested
Capital invested by funds: $754M → $793M (+$39.6M)
18% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 38
81% less call options, than puts
Call options by funds: $300K | Put options by funds: $1.59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$26M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$5.75M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$5.37M |
| 4 |
NTC
North Tide Capital
Boston,
Massachusetts
|
+$5.32M |
| 5 |
TCM
Tributary Capital Management
Omaha,
Nebraska
|
+$2.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.72M |
| 3 |
ICM
IronBridge Capital Management
Oakbrook Terrace,
Illinois
|
-$3.03M |
| 4 |
Renaissance Technologies
New York
|
-$2.86M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.53M |
GHDX Hedge Fund Activity: Q2 2014 in Review
112 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q2 2014, worth a combined $793M — up 5.3% from $754M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new GHDX positions and 8 closed out — a net gain of 12 holders — while 31 added to existing stakes and 38 trimmed.
The largest buyer was Camber Capital Management, adding an estimated $26M. The largest seller was Fidelity Investments, cutting an estimated $23.4M.
- 112 institutional investors held Genomic Health, Inc. (GHDX) as of Q2 2014, up from 101 in Q1 2014.
- Funds reported $793M of Genomic Health, Inc. stock for Q2 2014, up 5.3% quarter-over-quarter.
- 20 funds opened new Genomic Health, Inc. positions in Q2 2014 and 8 closed out, a net change of +12 holders.
- The largest Genomic Health, Inc. buyer in Q2 2014 was Camber Capital Management, an estimated $26M added.
- The largest Genomic Health, Inc. seller in Q2 2014 was Fidelity Investments, an estimated $23.4M sold.
Based on aggregated 13F filings for Q2 2014.